M. O’Shaughnessy

M. Schechter, C. Archibald, M. Ofner, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy

P. Harrigan, R. Hogg, J. Montaner, 2002, AIDS.

Use of pooling, and outpatient laboratory specimens in an anonymous seroprevalence survey of HIV infection in British Columbia, Canada

M. Schechter, S. Strathdee, M. O’Shaughnessy, 1995, AIDS.

The effects of pooling serum samples from seroconverting individuals or individuals with end stage disease for HIV antibody testing: a comparison of four screen tests and three pool sizes

J. Raboud, M. O’Shaughnessy, C. Sherlock, 1996 .

Females Experiencing Sexual and Drug Vulnerabilities Are at Elevated Risk for HIV Infection Among Youth Who Use Injection Drugs

M. Schechter, M. Tyndall, Kathy Li, 2002, Journal of acquired immune deficiency syndromes.

The Potential Public Health and Community Impacts of Safer Injecting Facilities: Evidence From a Cohort of Injection Drug Users

R. Hogg, M. Schechter, E. Wood, 2003, Journal of acquired immune deficiency syndromes.

Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help?

J. Montaner, M. Schechter, E. Wood, 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Pattern of utilization of rifabutin for prophylaxis of Mycobacterium avium complex among patients with advanced human immunodeficiency virus disease in a community setting.

R. Hogg, J. Montaner, M. Schechter, 1996, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.

Julio S. G. Montaner, Peter Phillips, R. Hogg, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program.

Julio S. G. Montaner, R. Hogg, W. Black, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Determinants of sexual risk-taking among young HIV-negative gay and bisexual men.

R. Hogg, J. Montaner, M. Schechter, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver.

M. Schechter, E. Wood, M. Tyndall, 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS

B. Yip, R. Hogg, J. Montaner, 2000, PharmacoEconomics.

The Vancouver Lymphadenopathy-AIDS Study: 5. Antecedent behavioural, clinical and laboratory findings in patients with AIDS and HIV-seropositive controls.

M. Schechter, M. O’Shaughnessy, K. Craib, 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Relation between hospital HIV/AIDS caseload and mortality among persons with HIV/AIDS in Canada.

R. Hogg, J. Montaner, M. Schechter, 1998, Clinical and investigative medicine. Medecine clinique et experimentale.

“They Don't See Our Feelings.” The Health Care Experiences of HIV-Positive Transgendered Persons

R. Hogg, M. Schechter, M. O’Shaughnessy, 1998 .

The changing spectrum of AIDS index diseases in Canada

R. Hogg, J. Montaner, M. Schechter, 1994, AIDS.

Low HIV‐1 proviral DNA burden detected by negative polymerase chain reaction in seropositive individuals correlates with slower disease progression

J. Montaner, M. Schechter, M. O’Shaughnessy, 1991, AIDS.

Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy.

R. Hogg, J. Montaner, M. Schechter, 2003, The Journal of infectious diseases.

Antiretroviral therapy: 'the state of the art'.

R. Hogg, J. Montaner, M. O’Shaughnessy, 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.

J. Montaner, M. Schechter, B. Conway, 1997, The Journal of infectious diseases.

Depressive symptoms decline among persons on HIV protease inhibitors.

B. Yip, R. Hogg, J. Montaner, 2000 .

"Being dealt with as a whole person." Care seeking and adherence: the benefits of culturally competent care.

R. Hogg, M. O’Shaughnessy, A. Schilder, 2001, Social science & medicine.

Antiretroviral Treatment Patterns and Incident HIV‐Associated Morphologic and Lipid Abnormalities in a Population‐Based Cohort

J. Singer, R. Hogg, J. Montaner, 2002 .

HIV-associated risk factors among young Canadian Aboriginal and non-Aboriginal men who have sex with men

R. Hogg, M. Schechter, S. Strathdee, 1999, International journal of STD & AIDS.

Clinical correlates of in vitro HIV‐1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial

J. Singer, J. Montaner, M. Wainberg, 1993, AIDS.

Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: Outcomes from a population-based cohort

R. Hogg, J. Montaner, M. Schechter, 2005, AIDS care.

Rectal gonorrhoea asan independent risk factor forHIVinfection inacohort ofhomosexual men

J. Montaner, M. Schechter, S. Strathdee, 1995 .

CCR5Δ32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response

P. Harrigan, R. Hogg, J. Montaner, 2001, AIDS.

Physician concurrence with primary care guidelines for persons with HIV disease

J. Singer, R. Hogg, J. Montaner, 1997, International journal of STD & AIDS.

Heterogeneity of physician agreement with recommended therapeutic guidelines for the management of HIV-associated disease.

R. Hogg, J. Montaner, M. Schechter, 1996, Antiviral therapy.

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

B. Yip, R. Hogg, J. Montaner, 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Determinants of hospital admission among HIV-positive people in British Columbia.

R. Hogg, J. Montaner, M. O’Shaughnessy, 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

A decade of research on the natural history of HIV infection: Part 2. Cofactors.

R. Hogg, J. Montaner, M. Schechter, 1996, Clinical and investigative medicine. Medecine clinique et experimentale.

The social determinants of emergency department and hospital use by injection drug users in Canada

R. Hogg, M. Schechter, A. Anis, 1999, Journal of urban health.

How otherwise dedicated AIDS prevention workers come to support state-sponsored shortage of clean syringes in Vancouver, Canada

M. Schechter, E. Wood, M. O’Shaughnessy, 2004 .

Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS.

S. Strathdee, M. O’Shaughnessy, S. Read, 1995, The Journal of infectious diseases.

Aetiology of AIDS

Julio S. G. Montaner, E. Vittinghoff, K. Gelmon, 1993, The Lancet.

Antiretroviral medication use among injection drug users: two potential futures

Julio S. G. Montaner, R. Hogg, J. Montaner, 2000, AIDS.

HIV/AIDS mortality in Canada: evidence of gender, regional and local area differentials.

R. Hogg, J. Montaner, M. Schechter, 1996, AIDS.

Characterization of Reverse Transcriptase Activity and Susceptibility to Other Nucleosides of AZT‐Resistant Variants of HIV‐1

J. Montaner, M. Wainberg, J. Ruedy, 1990, Annals of the New York Academy of Sciences.

Should we embrace new drugs with open arms? Experience from a community-based, open-arm, randomized clinical trial of combination antiretroviral therapy in advanced HIV disease.

R. Hogg, J. Montaner, M. Schechter, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

HIV/AIDS care giving physicians: their experience and practice patterns

R. Hogg, M. O’Shaughnessy, B. Yip, 1997, International journal of STD & AIDS.

INFLUENCE OF ZIDOVUDINE ON PROGRESSION TO AIDS IN COHORT STUDIES

Julio S. G. Montaner, M. Schechter, M. O’Shaughnessy, 1989, The Lancet.

Cessation of zidovudine therapy may lead to increased replication of HIV-1.

K. Gelmon, J. Montaner, M. Wainberg, 1989, Journal of the American Medical Association (JAMA).

Leaving hospital against medical advice among HIV-positive patients.

M. Schechter, A. Anis, D. Guh, 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Requiring Help Injecting as a Risk Factor for HIV Infection in

M. Schechter, E. Wood, T. Kerr, 2003 .

Requiring Help Injecting as a Risk Factor for HIV Infection in the Vancouver Epidemic

M. Schechter, E. Wood, T. Kerr, 2003, Canadian journal of public health = Revue canadienne de sante publique.

Surviving the sex trade: A comparison of HIV risk behaviours among street-involved women in two Canadian cities who inject drugs

M. Schechter, J. Bruneau, M. O’Shaughnessy, 2003, AIDS care.

Needle exchange and difficulty with needle access during an ongoing HIV epidemic

R. Hogg, M. Schechter, E. Wood, 2002 .

Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme.

R. Hogg, J. Montaner, M. Schechter, 2002, AIDS.

Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.

J. Singer, R. Hogg, J. Montaner, 2002, Journal of acquired immune deficiency syndromes.

Use of the Markov model to estimate the waiting times in a modified WHO staging system for HIV infection.

J. Montaner, M. Schechter, M. O’Shaughnessy, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Socio-Demographic Profile and Hiv and Hepatitis C Prevalence Among Persons Who Died of a Drug Overdose

R. Hogg, E. Wood, A. Palepu, 2001 .

The effect of cigarette smoking on lymphocyte subsets and progression to AIDS in a cohort of homosexual men.

J. Montaner, M. Schechter, R. Voigt, 1992, Clinical and investigative medicine. Medecine clinique et experimentale.

Adherence to guidelines for the prevention of HIV-related respiratory diseases.

J. Montaner, M. Schechter, M. O’Shaughnessy, 1996, The European respiratory journal.

HIV/AIDS epidemiology

R. Hogg, J. Montaner, P. Braitstein, 2000, The Lancet.

Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States.

B. Yip, R. Hogg, J. Montaner, 2002, AIDS.

Hospital utilization and costs in a cohort of injection drug users.

M. Schechter, A. Anis, A. Palepu, 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Mitochondrial Toxicity in the Era of HAART: Evaluating Venous Lactate and Peripheral Blood Mitochondrial DNA in HIV-Infected Patients Taking Antiretroviral Therapy

B. Yip, R. Hogg, J. Montaner, 2003, Journal of acquired immune deficiency syndromes.

Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Indirect costs of HIV/AIDS mortality in Canada

R. Hogg, J. Montaner, M. Schechter, 1994, AIDS.

The Vancouver Lymphadenopathy-AIDS Study: 2. Seroepidemiology of HTLV-III antibody.

B. Wiggs, M. Schechter, M. O’Shaughnessy, 1985, Canadian Medical Association journal.

Nature, time course and dose dependence of zidovudine‐related side effects: results from the Multicenter Canadian Azidothymidine Trial

K. Gelmon, J. Montaner, M. Wainberg, 1989, AIDS.

Oral corticosteroids in patients with mild Pneumocystis carinii pneumonia and the acquired immune deficiency syndrome (AIDS).

J. Montaner, M. Schechter, J. Ruedy, 1993, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world.

R. Hogg, J. Montaner, D. Bangsberg, 2003, AIDS.

Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.

R. Hogg, J. Montaner, M. Schechter, 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Impact of HIV infection and AIDS on death rates in British Columbia and Canada.

R. Hogg, J. Montaner, M. Schechter, 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak.

M. Schechter, S. Strathdee, S. Currie, 1999, AIDS.

Accuracy of a saliva test for HIV antibody.

J. Montaner, S. Marion, M. O’Shaughnessy, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Evan Wood, P. Harrigan, B. Yip, 2003, AIDS.

Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver.

R. Hogg, M. Schechter, E. Wood, 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Impact of HIV Infection on Mortality in a Cohort of Injection Drug Users

M. Schechter, S. Currie, M. Tyndall, 2001, Journal of acquired immune deficiency syndromes.

Antiviral effect of double and triple drug combinations amongst HIV‐infected adults: lessons from the implementation of viral load‐driven antiretroviral therapy

B. Yip, R. Hogg, J. Montaner, 1998, AIDS.

Determinants of complementary therapy use in HIV-infected individuals receiving antiretroviral or anti-opportunistic agents.

R. Hogg, J. Montaner, M. Schechter, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs.

B. Yip, R. Hogg, J. Montaner, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa

Evan Wood, Paula Braitstein, Martin T Schechter, 2000, The Lancet.

Evaluation of a human immunodeficiency virus test algorithm utilizing a recombinant protein enzyme immunoassay

M. O’Shaughnessy, P. Neumann, S. Frenette, 1990, Journal of clinical microbiology.

Toronto street youth and HIV/AIDS: prevalence, demographics, and risks.

M. O’Shaughnessy, M. Fearon, S. Read, 1999, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

Interferon inhibition of DNA synthesis and cell division.

M. O’Shaughnessy, S. H. Lee, K. Rozee, 1972, Canadian journal of microbiology.

The relationship between adenosine 3':5'-cyclic monophosphate (cAMP) and interferon activity in mouse cells.

R. B. Stewart, M. O’Shaughnessy, R. Stewart, 1980, The Journal of general virology.

Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men.

J. Montaner, M. Schechter, M. O’Shaughnessy, 1989, AIDS.

Adherence to triple therapy and viral load response.

R. Hogg, J. Montaner, M. O’Shaughnessy, 2000, Journal of acquired immune deficiency syndromes.

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

P. Harrigan, C. Alexander, J. Montaner, 2002, The New England journal of medicine.

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

R. Hogg, J. Montaner, M. Schechter, 1998, JAMA.

Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.

C. Alexander, J. Montaner, M. O’Shaughnessy, 2002, AIDS.

Time to act: global apathy towards HIV/AIDS is a crime against humanity

R. Hogg, J. Montaner, M. Wainberg, 2002, The Lancet.

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up

B. Yip, R. Hogg, J. Montaner, 2002, AIDS.

Adherence to Antiretroviral Therapy and Cd4 T-Cell Count Responses among HIV-Infected Injection Drug Users

B. Yip, R. Hogg, J. Montaner, 2004, Antiviral therapy.

Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies

B. Yip, R. Hogg, J. Montaner, 2003, AIDS.

Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995–2000

A. Levy, B. Yip, R. Hogg, 2003, AIDS.

Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Impaired Virologic Response to Highly Active Antiretroviral Therapy Associated With Ongoing Injection Drug Use

B. Yip, R. Hogg, J. Montaner, 2003, Journal of acquired immune deficiency syndromes.

Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response

P. Harrigan, R. Hogg, J. Montaner, 2003, AIDS.

Age, Adherence and Injection Drug use Predict Virological Suppression among Men and Women Enrolled in a Population-Based Antiretroviral Drug Treatment Programme

B. Yip, R. Hogg, J. Montaner, 2002, Antiviral therapy.

Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy

K. Hertogs, W. Verbiest, B. Larder, 2002, Antiviral therapy.

Highly Active Antiretroviral Therapy: Physician Experience and Enhanced Adherence to Prescription Refill

B. Yip, R. Hogg, J. Montaner, 2002, Antiviral therapy.

Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy

P. Harrigan, R. Hogg, J. Montaner, 2002, Antiviral therapy.

Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996

Evan Wood, Martin T Schechter, R. Hogg, 2002, AIDS.

"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.

B. Yip, R. Hogg, J. Montaner, 2002, Journal of acquired immune deficiency syndromes.

Comparison of Costs of Strategies for Measuring Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma by Using Amplicor and Ultra Direct Assays

P. Harrigan, R. Hogg, J. Montaner, 1998, Journal of Clinical Microbiology.

P. Harrigan, B. Yip, R. Hogg, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection

M. Schechter, S. Strathdee, S. Currie, 2022 .

Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation.

P. Harrigan, R. Hogg, J. Montaner, 1999, The Journal of infectious diseases.

Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database

R. Hogg, J. Montaner, M. O’Shaughnessy, 2001, AIDS.

The effect of zidovudine on platelet count in HIV-infected individuals.

K. Gelmon, M. Wainberg, J. Ruedy, 1990, Journal of acquired immune deficiency syndromes.

Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay, and hemagglutination inhibition test with neutralization test for determination of immune status

J. Weber, M. O’Shaughnessy, P. Neumann, 1985, Journal of clinical microbiology.

Human immunodeficiency virus type 1 long terminal repeat variants from 42 patients representing all stages of infection display a wide range of sequence polymorphism and transcription activity

J. Montaner, I. Sadowski, A. Merzouki, 1996, Journal of virology.

Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection.

J. Montaner, M. Schechter, B. Conway, 1996, The Journal of infectious diseases.

Hck SH3 domain‐dependent abrogation of Nef‐induced class 1 MHC down‐regulation

F. Jirik, M. O’Shaughnessy, A. Chang, 2001, European journal of immunology.

Purification of RBF-2, a Transcription Factor with Specificity for the Most Conserved cis-Element of Naturally Occurring HIV-1 LTRs

M. Hirst, I. Sadowski, M. O’Shaughnessy, 1999, Journal of Biomedical Science.

Purification of RBF-2, a transcription factor with specificity for the most conserved cis-element of naturally occurring HIV-1 LTRs.

M. Hirst, I. Sadowski, M. O’Shaughnessy, 1999, Journal of biomedical science.

Sexual violence among a cohort of injection drug users.

R. Hogg, M. Schechter, P. Braitstein, 2003, Social science & medicine.

Needle exchange is not enough: lessons from the Vancouver injecting drug use study

Julio S. G. Montaner, M. Schechter, S. Strathdee, 1997, AIDS.

Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure.

Evan Wood, Kathy Li, Martin T Schechter, 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) mortality in industrialized nations, 1987-1991.

R. Hogg, J. Montaner, M. Schechter, 1998, International journal of epidemiology.

Incarceration, Addiction and Harm Reduction: Inmates Experience Injecting Drugs in Prison

M. Schechter, M. O’Shaughnessy, P. Spittal, 2005, Substance use & misuse.

Determinants of HIV seroconversion in drug users during a period of rising prevalence in Vancouver

M. Schechter, C. Archibald, M. Ofner, 1997 .

Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users.

P. Harrigan, C. Alexander, J. Montaner, 1999, AIDS.

An anonymous seroprevalence survey of HIV infection among pregnant women in British Columbia and the Yukon Territory.

M. Schechter, S. Marion, M. O’Shaughnessy, 1990, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Modelling the Potential Economic Impact of Viral Load—Driven Triple Drug Combination Antiretroviral Therapy

B. Yip, R. Hogg, J. Montaner, 1998, PharmacoEconomics.

Elevated rates of antiretroviral treatment discontinuation among HIV-infected injection drug users: implications for drug policy and public health

Julio S. G. Montaner, B. Yip, R. Hogg, 2004 .

Association of Phenotypic Changes in B Cell Lymphocytes and Plasma Viral Load in Human Immunodeficiency Virus-Infected Patients

J. Montaner, B. Conway, M. O’Shaughnessy, 1998, Journal of Clinical Immunology.

Total Lymphocyte Count as a Possible Surrogate of Cd4 Cell Count to Prioritize Eligibility for Antiretroviral Therapy among HIV-Infected Individuals in Resource-Limited Settings

B. Yip, R. Hogg, J. Montaner, 2002, Antiviral therapy.

Antiretroviral treatment in 1998

R. Hogg, J. Montaner, J. Raboud, 1998, The Lancet.

Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection.

R. Hogg, J. Montaner, M. Schechter, 1997, Journal of Infectious Diseases.

Emerging international consensus for use of antiretroviral therapy

R. Hogg, J. Montaner, M. O’Shaughnessy, 1997, The Lancet.

Sources and Magnitude of Intralaboratory Variability in a Sequence-Based Genotypic Assay for Human Immunodeficiency Virus Type 1 Drug Resistance

P. Harrigan, B. Wynhoven, M. O’Shaughnessy, 2003, Journal of Clinical Microbiology.

HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort

Julio S. G. Montaner, Michael V. O'Shaughnessy, P. Harrigan, 2001, AIDS.

Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use.

R. Hogg, J. Montaner, S. Strathdee, 2001, AIDS.

Determinants of geographic mobility among participants in a population-based HIV/AIDS drug treatment program.

R. Hogg, J. Montaner, M. Schechter, 2000, Health & place.

Barriers to use of free antiretroviral therapy in injection drug users.

B. Yip, R. Hogg, J. Montaner, 1998, JAMA.

Lower socioeconomic status and shorter survival following HIV infection

Julio S. G. Montaner, R. Hogg, M. Schechter, 1994, The Lancet.

Decline in deaths from AIDS due to new antiretrovirals

B. Yip, R. Hogg, J. Montaner, 1997, The Lancet.

The impact of antiretroviral therapy on AIDS survival observed in a province-wide drug treatment programme.

R. Hogg, J. Montaner, M. Schechter, 1998, International journal of STD & AIDS.

“A Lot of Things I Hide”: Understanding Disclosure in the Care of HIV-Positive Bisexual Men

R. Hogg, S. Strathdee, M. O’Shaughnessy, 1999 .

Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens

P. Harrigan, B. Yip, R. Hogg, 2001, AIDS.

HTLV-III infection in Canada in 1985.

M. O’Shaughnessy, D. Robinson, N. Gilmore, 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

The Vancouver Lymphadenopathy-AIDS Study: 6. HIV seroconversion in a cohort of homosexual men.

M. Schechter, M. O’Shaughnessy, K. Craib, 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Susceptibility to AIDS progression appears early in HIV infection

J. Montaner, M. Schechter, M. O’Shaughnessy, 1990, AIDS.

Long-term non-progression in HIV infection

Julio S. G. Montaner, R. Hogg, M. Schechter, 1995, The Lancet.

Isolation of drug‐resistant variants of HIV‐1 from patients on long‐term zidovudine therapy

K. Gelmon, J. Montaner, M. Wainberg, 1989, AIDS.

Patterns of sexual behavior and condom use in a cohort of homosexual men.

M. Schechter, M. O’Shaughnessy, K J Craib, 1988, American journal of public health.

Evidence for a Sexually Transmitted Cofactor for AIDS-Related Kaposi's Sarcoma in a Cohort of Homosexual Men

J. Montaner, M. Schechter, C. Archibald, 1992, Epidemiology.

HIV infection and risk behaviours among young gay and bisexual men in Vancouver.

R. Hogg, M. Schechter, S. Strathdee, 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Risk factors for Kaposi's sarcoma in the Vancouver Lymphadenopathy-AIDS Study.

M. Schechter, C. Archibald, M. O’Shaughnessy, 1990, Journal of acquired immune deficiency syndromes.

Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection.

J. Singer, R. Hogg, J. Montaner, 2003, Current drug targets.

AIDS Upda te Laboratory diagnosis of the first cases of HIV-2 infection Canada

M. O’Shaughnessy, C. Major, B. McLaughlin, 2005 .

Monoclonal idiotypic and anti-idiotypic antibodies to human immunodeficiency virus type 1 envelope glycoprotein.

M. O’Shaughnessy, S. Faucher, J. Hamel, 1991, The Journal of general virology.

Detection of antibody to HTLV-III by commercial kits.

M. O’Shaughnessy, P. Neumann, B. Benning, 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

THROUGH THE LOOKING GLASS : THE HEALTH AND SOCIO-ECONOMIC STATUS OF HEPATITIS C POSITIVE TRANSFUSION RECIPIENTS , 1986-1990

R. Hogg, M. Schechter, M. O’Shaughnessy, 1999 .

Prescribing practices in a population-based HIV postexposure prophylaxis program

R. Hogg, J. Montaner, P. Braitstein, 2002, AIDS.

A reality check: the cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk.

R. Hogg, J. Montaner, K. Bartholomew, 2000, AIDS.

B. Yip, R. Hogg, J. Montaner, 2004, Quality of Life Research.

Adherence to clinical guidelines for the therapeutic management of HIV disease.

J. Singer, R. Hogg, J. Montaner, 1997, Clinical and investigative medicine. Medecine clinique et experimentale.

Impact of HIV infection on mortality in a cohort of injection drug users.

M. Schechter, S. Currie, M. Tyndall, 2001 .

Risky sexual behaviours among injection drugs users with high HIV prevalence: implications for STD control

M. Schechter, M. Tyndall, Kathy Li, 2002, Sexually transmitted infections.

Satellite Needle Distribution Among Injection Drug Users: Policy and Practice in Two Canadian Cities

M. Schechter, J. Bruneau, M. Tyndall, 2002, Journal of acquired immune deficiency syndromes.

Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver.

M. Schechter, C. Archibald, M. Ofner, 1997, International journal of STD & AIDS.

HIV-Positive Injection Drug Users Who Leave the Hospital Against Medical Advice: The Mitigating Role of Methadone and Social Support

M. Schechter, A. Anis, D. Guh, 2004, Journal of acquired immune deficiency syndromes.

Stavudine plus lamivudine in advanced human immunodeficiency virus disease: a short-term pilot study.

J. Montaner, D. Rouleau, B. Conway, 1997, The Journal of infectious diseases.